Subscribe To
nexcella, immix biopharma subsidiary, to present at the bank of america 2023 healthcare trailblazers private company conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical...
September 7, 2023, 12:41 pm
nexcella announces dr. suzanne lentzsch, director of the multiple myeloma and amyloidosis program at the college of physicians and surgeons of columbia university and at new york presbyterian hospital
Dr. Lentzsch joins the nexcella Scientific Advisory Board with decades of experience treating patients ...
September 1, 2023, 12:44 pm
Immix biopharma announces dr. suzanne lentzsch, director of the multiple myeloma and amyloidosis program at the college of physicians and surgeons of columbia university and at new york presbyterian h
Dr. Lentzsch joins the nexcella Scientific Advisory Board with decades of experience treating patients ...
September 1, 2023, 12:39 pm
nexcella appoints mary sue coleman, former johnson & johnson independent director, to board of directors
Dr. Coleman joins the nexcella, Inc. Board of Directors with over a decade of experience as an Independ...
June 16, 2023, 1:48 pm
nexcella announces commencement of nxc-201 engineering batches at its u.s. car-t manufacturing site
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineeri...
May 26, 2023, 1:58 pm
Immix biopharma subsidiary nexcella announces commencement of nxc-201 engineering batches at its u.s. car-t manufacturing site
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineeri...
May 26, 2023, 1:53 pm
nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:05 pm
nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:05 pm
nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:05 pm
nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:05 pm
nexcella announces late-breaking nxc-201 clinical data abstract accepted for oral presentation at the 26th annual meeting of the american society of gene and cell therapy (asgct)
•Updated clinical data for next-generation CAR-T NXC-201 in AL amyloidosis will be presented in Los Angeles May 16-20, 2023 LOS ANGELES, May 04, 202...
May 4, 2023, 4:35 pm
nexcella, inc. presents 42-patient interim data, with 90% overall response rate in relapsed or refractory multiple myeloma at nxc-201 therapeutic dose from its phase 1 expansion trial at the 5th europ
The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 re...
February 9, 2023, 1:05 pm
nexcella, inc announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car t-cell meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:05 pm
nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm